Current and Future Development in Lung Cancer Diagnosis
- PMID: 34445366
- PMCID: PMC8395394
- DOI: 10.3390/ijms22168661
Current and Future Development in Lung Cancer Diagnosis
Abstract
Lung cancer is the leading cause of cancer-related deaths in North America and other developed countries. One of the reasons lung cancer is at the top of the list is that it is often not diagnosed until the cancer is at an advanced stage. Thus, the earliest diagnosis of lung cancer is crucial, especially in screening high-risk populations, such as smokers, exposure to fumes, oil fields, toxic occupational places, etc. Based on the current knowledge, it looks that there is an urgent need to identify novel biomarkers. The current diagnosis of lung cancer includes different types of imaging complemented with pathological assessment of biopsies, but these techniques can still not detect early lung cancer developments. In this review, we described the advantages and disadvantages of current methods used in diagnosing lung cancer, and we provide an analysis of the potential use of body fluids as carriers of biomarkers as predictors of cancer development and progression.
Keywords: biomarkers; body fluids; diagnosis; imaging; lung cancer; predictors.
Conflict of interest statement
Authors reported no conflict of interest.
Similar articles
-
Circulating microRNA signature as liquid-biopsy to monitor lung cancer in low-dose computed tomography screening.Oncotarget. 2015 Oct 20;6(32):32868-77. doi: 10.18632/oncotarget.5210. Oncotarget. 2015. PMID: 26451608 Free PMC article.
-
Molecular approaches to lung cancer prevention.Future Oncol. 2021 May;17(14):1793-1810. doi: 10.2217/fon-2020-0789. Epub 2021 Mar 3. Future Oncol. 2021. PMID: 33653087 Review.
-
[The causes of increased risk for lung cancer in the pulp and paper industry workers. The effect of smoking and exposure to chemicals].Med Pr. 1999;50(1):3-14. Med Pr. 1999. PMID: 10399712 Polish.
-
New research finds lung cancer screening guidelines are insufficient for firefighters.Cancer. 2020 Feb 15;126(4):692-693. doi: 10.1002/cncr.32721. Cancer. 2020. PMID: 31995245 No abstract available.
-
Asbestos-related lung cancer and malignant mesothelioma of the pleura: selected current issues.Semin Respir Crit Care Med. 2015 Jun;36(3):334-46. doi: 10.1055/s-0035-1549449. Epub 2015 May 29. Semin Respir Crit Care Med. 2015. PMID: 26024342 Review.
Cited by
-
CircRNAs: Pivotal modulators of TGF-β signalling in cancer pathogenesis.Noncoding RNA Res. 2024 Jan 26;9(2):277-287. doi: 10.1016/j.ncrna.2024.01.013. eCollection 2024 Jun. Noncoding RNA Res. 2024. PMID: 38505309 Free PMC article. Review.
-
Illuminating Shared Genetic Associations Between Oesophageal Carcinoma and Pulmonary Carcinoma Risk.J Cancer. 2024 Mar 4;15(8):2412-2423. doi: 10.7150/jca.92899. eCollection 2024. J Cancer. 2024. PMID: 38495498 Free PMC article.
-
Understanding the Landscape of Bronchoscopy in Lung Cancer: Insights From Lesion Location, Gender, and Diagnostic Efficacy.Cureus. 2024 Feb 9;16(2):e53918. doi: 10.7759/cureus.53918. eCollection 2024 Feb. Cureus. 2024. PMID: 38465029 Free PMC article.
-
Transcriptome profiling and metabolic pathway analysis towards reliable biomarker discovery in early-stage lung cancer.J Appl Genet. 2024 Mar 5. doi: 10.1007/s13353-024-00847-2. Online ahead of print. J Appl Genet. 2024. PMID: 38443694
-
Exploration of Ginkgo biloba leaves on non-small cell lung cancer based on network pharmacology and molecular docking.Medicine (Baltimore). 2024 Mar 1;103(9):e37218. doi: 10.1097/MD.0000000000037218. Medicine (Baltimore). 2024. PMID: 38428907 Free PMC article.
References
-
- Mercer R. Canadian Cancer Statistics: A 2020 Special Report on Lung Cancer. Canadian Centre for Applied Research in Cancer Control; Vancouver, BC, Canada: 2020.
-
- Horeweg N., Scholten E.T., de Jong P.A., van der Aalst C.M., Weenink C., Lammers J.-W.J., Nackaerts K., Vliegenthart R., ten Haaf K., Yousaf-Khan U.A., et al. Detection of Lung Cancer through Low-Dose CT Screening (NELSON): A Prespecified Analysis of Screening Test Performance and Interval Cancers. Lancet Oncol. 2014;15:1342–1350. doi: 10.1016/S1470-2045(14)70387-0. - DOI - PubMed
-
- Gartman E.J., Jankowich M.D., Baptiste J., Nici L. A98. Clinical Strategies to Improve Lung Cancer Early Detection: Who Is at Risk Here? American Thoracic Society International Conference Abstracts. American Thoracic Society; New York, NY, USA: 2018. Providence VA lung cancer screening program: Performance: Comparison of local false positive and invasive procedure rates to published trial data; p. A2477.
-
- Kuman V., Abbas A., Fausto N., Robbins S., Cotran R. Robbins and Cotran Pathologic Basis of Disease. Elsevier Saunders; Philadelphia, PA, USA: 2005. p. 759.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
